Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy

The HELIOS B trial, recently published in NEJM, has unveiled promising results for patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM). Vutrisiran, a cutting-edge siRNA therapy, significantly reduced the risk of death and cardiac events compared to placebo. Over 36 months, Vutrisiran also showed improvements in walking distance and quality of life. These findings highlight a potential breakthrough in managing ATTR-CM.